The Role of Vascular Endothelial Growth Factor in Wound Healing

Philip Bao, M.D.,* Arber Kodra, B.A.,† Marjana Tomic-Canic, Ph.D.,‡ Michael S. Golinko, M.D.,§ H. Paul Ehrlich, Ph.D.,¶ and Harold Brem, M.D.§1

*University of Pittsburgh, Department of Surgery, Pittsburgh, Pennsylvania; †New York Medical College, Valhalla, New York; ‡Hospital for Special Surgery, Tissue Engineering, Regeneration and Repair Program, New York, New York; §New York University School of Medicine, Department of Surgery, Division of Wound Healing and Regenerative Medicine, New York, New York; and 1Division of Plastic Surgery, Pennsylvania State Medical Center, Hershey, Pennsylvania

Submitted for publication January 11, 2008

Background. A chronic wound is tissue with an impaired ability to heal. This is often a consequence of one of the following etiologies: diabetes, venous reflux, arterial insufficiency sickle cell disease, steroids, and/or pressure. Healing requires granulation tissue depending on epithelialization and angiogenesis. Currently no growth factor is available to treat patients with impaired healing that stimulates both epithelialization and angiogenesis. The objective is to review the multiple mechanisms of vascular endothelial growth factor (VEGF) in wound healing.

Materials and Methods. The authors reviewed the literature on the structure and function of VEGF, including its use for therapeutic angiogenesis. Particular attention is given to the specific role of VEGF in the angiogenesis cascade, its relationship to other growth factors and cells in a healing wound.

Results. VEGF is released by a variety of cells and stimulates multiple components of the angiogenic cascade. It is up-regulated during the early days of healing, when capillary growth is maximal. Studies have shown the efficacy of VEGF in peripheral and cardiac ischemic vascular disease with minimal adverse effects. Experimental data supports the hypothesis that VEGF stimulates epithelialization and collagen deposition in a wound.

Conclusion. VEGF stimulates wound healing through angiogenesis, but likely promotes collagen deposition and epithelialization as well. Further study of the molecule by utilizing the protein itself, or novel forms of delivery such as gene therapy, will increase its therapeutic possibilities to accelerate closure of a chronic wound. © 2009 Elsevier Inc. All rights reserved.

Key Words: VEGF; wound healing; angiogenesis; epithelialization; keratinocyte; fibroblast.

INTRODUCTION

The term “chronic wound” describes a wound that occurs in a patient who has physiological impairments to healing (Table 1). These pathophysiologic processes predispose cutaneous wounds to deviate from the characteristics of acute wound healing. Although a chronic wound is not always slow to heal, it should be considered “emergent” in that it is often a nonhealing wound. An estimated 3 to 6 million chronic skin ulcers occur in patients every year in the United States. The most common underlying conditions are venous reflux, pressure, and diabetes mellitus [1–5].

In the vast majority of surgical procedures, nearly all acute wounds heal in an orderly and timely process [6], with a strength and integrity similar to normal skin [7, 8]. Wounds refractory to moist healing, however, may be candidates for growth factor therapy, which is assumed to stimulate missing or dysfunctional components of the chronic wound [9–11]. An angiogenic growth factor may promote closure of chronic wounds exhibiting hypoxia and compromised vascularity.

Vascular endothelial growth factor (VEGF) is one such candidate. It functions as an endothelial cell mitogen [12–17], chemotactic agent [18, 19], and inducer of vascular permeability [20–26]. Other angiogenic
growth factors such as basic fibroblast growth factor (bFGF) and transforming growth factor beta (TGF-β) have been described, but VEGF is unique for its effects on multiple components of the wound-healing cascade, including angiogenesis and recently shown epithelialization and collagen deposition [27]. Purified growth factors [28] and cultured human cells [29–31] have both been approved by the Food and Drug Administration to accelerate closure of nonhealing wounds. This has transformed the field of wound healing by establishing the efficacy of a topical growth factor and cell therapy. Since angiogenesis maintains a critical role in wound healing, in the future, VEGF (alone or in combination therapy) may be used on patients with nonhealing wounds. This article reviews the role of angiogenesis and other mechanisms of VEGF in wound healing.

STRUCTURE AND HETEROGENEITY

VEGF is a homodimeric glycoprotein that shares almost 20% amino acid homology with platelet-derived growth factor (PDGF) [16]. VEGF exists in 5 isoforms resulting from alternative splicing of its mRNA, with chain lengths of 121, 145, 165, 189, and 206 amino acids [32–35]. These 5 forms are commonly referred to as VEGF-A (VEGF165), VEGF-B, VEGF-D, and placental growth factor. In addition, VEGF-C has been shown to be secreted by macrophages and their role in wound healing has begun to be investigated [36]. As the chain length increases, VEGF changes from a weakly acidic to a basic form, which enhances the ability of the molecule to bind heparin at its carboxy-terminus. Conversely, the amino-terminus of VEGF contains a signal sequence for protein secretion [15]. The bioavailability of VEGF depends upon its isoform, where VEGF121 is freely secreted, and where VEGF189 and VEGF206 are secreted, but largely bound to heparin residing on cell surfaces. VEGF145 and VEGF165 isoforms show intermediate characteristics, with equally bound and free forms. The balance of free versus bound VEGF has important implications for systemic versus local effects. VEGF165 is the most studied and available isoform and this review of VEGF will refer to this isoform exclusively.

SYNTHESIS AND RECEPTORS

Cells in a Healing Wound Synthesize VEGF

VEGF is produced by many cell types that participate in wound healing: endothelial cells [37, 38], fibroblasts [39], smooth muscle cells [40, 41], platelets [42], neutrophils [43], and macrophages [44]. The dominant isoform of VEGF is the shorter variant, which is soluble in the extracellular space.

VEGF Receptors

In humans, VEGF binds with receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2), both high affinity receptors [45–47]. They are members of the Type 3 tyrosine kinase family, consisting of 7 immunoglobulin-like extracellular domains, a single transmembrane spanning domain, and an intracellular tyrosine kinase domain. Two additional receptors have been designated low-affinity/molecular mass VEGF receptors, but their structure and function are not well characterized [48]. KDR and Flt-1 are localized to the endothelial surface of developing and mature blood vessels [49–51]. KDR and Flt-1 are only 37 and 45% homologous in their extracellular and kinase domains, respectively [52]. Mutational mouse studies of VEGF receptor genes have shown that Flk-1, the mouse homologue of KDR, is important for endothelial cell differentiation, whereas Flt-1 is required for organization of blood vessels [53, 54]. VEGF induces membrane ruffling, chemotaxis, and proliferation in endothelial cells expressing only KDR, but not in those exclusively expressing Flt-1 [55]. KDR mediates the mitogenic and chemotactic activities of VEGF. The roles of Flt-1 are less certain, but its functions may include the mediation of vascular permeability [56], the chemotactic response of neutrophils and macrophages [57], the expression of matrix metalloproteinases in vascular smooth muscle cells [58], and the induction of anti-apoptotic proteins [59]. A third tyrosine kinase receptor VEGFR3 (Flt-4) has also been characterized [60, 61]. Since that time, this receptor has been shown to mediate primarily lymphangiogenesis [62, 63].

VEGF STIMULATES MULTIPLE COMPONENTS OF THE ANGIOGENIC CASCADE

One of VEGF’s roles in wound healing is stimulation of angiogenesis. Wound-healing angiogenesis involves multiple steps including vasodilation, basement membrane degradation, endothelial cell migration, and endothelial cell proliferation [64]. Subsequently, capillary tube formation occurs, followed by anastomosis of parallel capillary sprouts (loop formation), and finally, new basement membrane formation. VEGF plays a role in several of these processes (Fig. 1).
A unique property of VEGF is its ability to increase vascular permeability [65]. Before its amino acid sequence was known, VEGF was designated vascular permeability factor. VEGF is more potent than histamine in inducing vascular leakage [17, 20, 21]. It binds to the KDR receptor, stimulating nitric oxide synthase and cyclooxygenase activities [65]. Nitric oxide (NO) and prostacyclin promote simultaneous vasodilation and vascular permeability [66, 67]. Vasodilation and accompanying stretch may also increase endothelial sensitivity to growth factors [64], as well as induce further VEGF expression in a positive feedback loop [68].

Degradation of Basement Membrane

VEGF induces procoagulant factors in endothelial cells, such as Von Willebrand factor, which mediates platelet adhesion and aggregation [69]. Platelets themselves synthesize and release VEGF [42], thereby increasing local concentration of protein, activating the coagulation cascade and the ultimate generation of thrombin and fibrin. Thrombin activates endothelial progelatinase A. VEGF directly increases endothelial cell secretion of interstitial collagenase (matrix metalloproteinase [MMP]-1), tissue inhibitor of metalloproteinases, and gelatinase A (MMP-2) [70]. VEGF also induces dose-dependent expression of urokinase-type and tissue-type plasminogen activator (uPA and tPA) as well as plasminogen activator inhibitor-1 [71]. In addition, VEGF stimulates vascular smooth muscle cells to express MMP-1, MMP-3, and MMP-9 [58].

The local vascular environment induced by VEGF represents a balance of enzymatic promoters and inhibitors, setting the stage for endothelial migration. MMP-2 may degrade type 4 collagen, a constituent of vascular basement membranes. MMP-1 breaks down collagen types 1–3 [70]. Plasmin cleaves the heparin-binding carboxy-termini of VEGF isoforms 165, 189, and 206, releasing their active soluble forms [34]. Consequently, enzymatic activity can promote further VEGF release. The resultant proteolytic environment destroys structural elements of the basement membrane and extracellular matrix, facilitating endothelial movement into the extravascular space.
**Endothelial Cell Migration**

VEGF induces endothelial cell migration in wound healing through 2 primary mechanisms, chemotaxis and vasodilation.

In the initial phase of angiogenesis, endothelial cells migrate before mitotic division [18]. Capillary budding may also be sustained for up to 4 or 5 d by endothelial elongation and migration without proliferation. How VEGF stimulates endothelial cell migration is detailed below.

**Mechanism I: Chemotaxis**

Chemotaxis is a highly regulated process involving cell adhesion molecules’ interaction with the extracellular matrix. VEGF-induced angiogenesis in the rabbit cornea and chick chorioallantoic membrane involved participation of $\alpha_\beta$ integrin [64]. VEGF also induces expression of uPA, which is required for $\alpha_\beta$-directed endothelial cell migration on vitronectin [72]. In vitro models, however, demonstrate that VEGF enhances not only the expression of the $\alpha_\beta$ integrin but also that of the $\alpha_\beta$ integrin [73, 74]. Furthermore, VEGF induces osteopontin (OPN), an $\alpha_\beta$ ligand, and both OPN and thrombin-cleaved OPN are chemotact for dermal endothelial cells [74]. The role of these integrins and whether VEGF is selective for a specific integrin pathway during angiogenesis and wound healing remain a promising area of study.

**Mechanism II: Increasing Vascular Permeability**

Another mechanism by which VEGF induces endothelial cell migration in wound healing is related to the increase in vascular permeability mediated by NO and prostacyclin. Leakage of the plasma protein fibrinogen and its subsequent conversion in the extracellular space to a fibrin gel stimulates endothelial migration.

**Endothelial Cell Proliferation**

VEGF is described as a mitogen selective for endothelial cells. It is unclear which molecules transduce the mitogenic signal, but NO and cyclic guanosine monophosphate appear to be involved [75]. VEGF induces endothelial cells grown on the surface of a collagen matrix to invade the underlying matrix [76] and stimulates their proliferative response [77].

Furthermore, VEGF delays senescence and restores proliferative capacity to endothelial cells [78]. It lengthens the lifespan of endothelial cells and prevents apoptosis by inducing the transient expression of 2 anti-apoptotic proteins in human endothelial cells [79]. These proteins may be responsible for VEGF’s prevention of apoptosis, induced by tumor necrosis factor-alpha (TNF-\(\alpha\)) in endothelial cells and by ionizing radiation in hematopoietic stem cells [59, 80].

VEGF may also mediate the survival effect by maintaining cell attachment through stimulation of fibronectin and $\beta_3$ integrin expression [80]. Similarly, VEGF inhibits apoptosis in cells cultured on nonsupportive, hydrophobic surfaces, but this involves increased expression of $\alpha_\beta$ integrin and deposition of vitronectin [81]. Inhibition of apoptosis is also achieved through inhibition of pro-apoptotic signaling, including forkhead [82] or activation of caspase-3 [83]. Thus, the increased replication and increased absolute lifespan of endothelial cells augments VEGF-induced proliferation. In addition, the proliferative and anti-apoptotic properties of VEGF have been shown to be partially mediated by either MAP2K1/2/MAPK3/1 and PI3K/akt1 pathways [79, 84–86] with subsequent inhibition of pro-apoptotic signaling [82].

**VEGF and Wound Healing**

An essential feature of normal wound repair is the formation of granulation tissue, i.e., fibrovascular tissue containing fibroblasts, collagen, and blood vessels, which is the hallmark of an established healing response. The vascular component depends upon angiogenesis, in which new vessels appear as early as d 3 after wounding [87]. Capillary growth into the wound subsequently provides a conduit for nutrients and other mediators of the healing response as well as removal of metabolites. Inhibition of angiogenesis impairs wound healing [88–90].

**Early Cells in a Healing Wound Synthesize and Release VEGF**

Various cellular responses to a wound involve the release of VEGF (Fig. 2). The platelet is the first vascular
component to appear in the wound site, followed by neutrophils, and then macrophages [87]. Activated platelets release VEGF, particularly after thrombin stimulation [42, 91].

Monocytes play both a direct and an indirect role in the angiogenic effects during wound healing. Monocytes express the VEGF receptor Flt-1 and respond chemotactically to VEGF [52]. Once recruited to the tissue, macrophages induce angiogenesis, in part by releasing TNF-α, which may in turn induce VEGF expression in keratinocytes and fibroblasts [92–94].

Cells involved in healing release cytokines and growth factors that may act as paracrine factors for further VEGF expression (Table 2). Factors that induce VEGF transcription and secretion include the following: TGF-β1, epidermal growth factor, TGF-α, and keratinocyte growth factor (from keratinocytes [93]) and arterial smooth muscle cells [40] and bFGF, PDGF-BB, and IL-1β (from aortic smooth muscle cells [41]).

**Hypoxia Induces VEGF**

Metabolic derangements of the wound environment up-regulate VEGF. Ischemia and hypoxia are characteristic of tissue damage, where oxygen tension in the wound is 6–7 mm Hg after 5 d, compared to normal tissue levels of 45–50 mm Hg [95, 96]. Angiogenesis restores tissue perfusion, reestablishes microcirculation, and increases oxygen tension to 30–40 mm Hg [96]. Thus, hypoxia enhances VEGF expression in monocytes as well as a variety of other cell types, including fibroblasts, keratinocytes, myocytes, and endothelial cells [38, 97–99]. Adenosine has been shown to mediate this hypoxic response [100, 101], and subsequent transduction pathways increase both VEGF mRNA transcription and half-life [102–104].

Similarly, hypoxia stimulates Flt-1 receptor expression on cultured endothelial cells [97]. Hypoxic cultures acutely down-regulate KDR expression, rendering it undetectable after 24 h. Long-term exposure to hypoxia for 72 h, however, results in KDR receptor reception [97, 101].

Hypoxia up-regulates tissue expression of VEGF and its receptors, which in turn promote an angiogenic response. Hypoxia, through inducible factor-1alpha, induces the expression of VEGF [105, 106]. A gradient of VEGF expression is established that parallels the hypoxic gradient, and endothelial cells subsequently migrate toward the most hypoxic areas. Macrophages help maintain the gradient, as they can survive in areas with the lowest oxygen tensions [96]. Indeed, a hypoxic tissue gradient is mandatory for wound-healing-related angiogenesis, and removal of that gradient inhibits capillary growth [107].

VEGF Presents in Wounds in a Specific Temporal Pattern

VEGF transcription and secretion are elevated in partial [108] and full-thickness skin wounds [93, 109]. In partial thickness wounds, keratinocytes at the wound edge express elevated VEGF as early as 1 d after injury and eventually migrate to cover the defect. Epidermal labeling for VEGF mRNA reaches a peak after 2–3 d, coincident with a peak in vascular permeability, and levels remain elevated until epidermal coverage is complete. Likewise, maximal VEGF mRNA is found between 3 and 7 d after full-thickness wounding, during the period of granulation tissue formation [93]. In these deeper wounds, VEGF is localized primarily to fibroblasts and macrophages [39]. A corresponding increase in Flt-1 expression occurs in dilated vessels bordering the wound at 3 d, and within the wound at 7 d postinjury [50]. Similarly, MMP-1, MMP-2, and tissue inhibitor of metalloproteinases-1, each inducible by VEGF, peak 2 to 5 d after excisional wounding [110].

The time course of VEGF expression provides insight into the progression of wound healing. During the proliferative phase of repair occurring approximately 3 to 7 d post-wounding capillary growth and differentiation are at a maximum. During this period, VEGF is up-regulated to promote the early stages of angiogenesis (i.e., vascular dilation, permeability, migration, and proliferation) [39]. Antibody neutralization of VEGF diminishes the chemotactic and angiogenic properties of wound fluid, thus revealing further evidence for the importance of VEGF in wound repair [39].

In contrast to the VEGF, bFGF may be an initial stimulus for angiogenesis, because elevated levels are found immediately in surgical wound fluid, but decline to serum levels by d 3 [39, 111]. This is consistent with sequestration of preformed bFGF in normal tissue and its release from cellular and interstitial sites [64, 112]. Significant expression of bFGF in wound tissue, however, begins approximately 8 d after full-thickness wounding and peaks at 12–14 d [113].

Given these data, a temporal model for angiogenesis during cutaneous wound healing may be described. Preformed bFGF is released upon injury, possibly helping to initiate VEGF expression from nearby vascular smooth muscle and endothelial cells, especially in combination with hypoxia [41, 114]. It may also promote a proteolytic environment needed for angiogenesis, as neutralization of bFGF blocks VEGF-induced uPA and tPA expression as well as angiogenesis [115].

As bFGF declines, a surge in VEGF from epidermal cells and macrophages induces and maintains early angiogenic steps by the 2nd or 3rd d after wounding. The influence of VEGF diminishes when inducers of VEGF like hypoxia decrease, or when factors like bFGF predominate in regulating the later stages of angiogenesis, such as lumen formation and basement membrane development. Accordingly, VEGF declines to
basal levels after 1 wk, just as bFGF begins its second increase, due to the numbers of endothelial cells and fibroblasts expressing bFGF. This model may explain in part the observed action between VEGF and bFGF, such that each is critical to early and late angiogenic steps, respectively.

Integrins associated with VEGF activity follow a similar pattern of expression in wound healing. In full-thickness wounds at d 3 and 4, $\alpha_\beta_3$ integrin is localized on hypertrophied vessels at the wound margin as well as on the tips of capillary sprouts invading the fibrin clot. Expression of $\alpha_\beta_3$ disappears by d 7, as VEGF returns to baseline levels [116]. Inhibition of granulation tissue formation and angiogenesis by neutralization of $\alpha_\beta_3$ emphasizes the importance of this integrin to wound healing [116, 117].

In summary, direct and indirect evidence implicates VEGF as a significant factor in wound healing immediately after injury. Induced by inflammatory cells and local wound conditions, VEGF potentially alleviates tissue hypoxia and metabolic deficiencies by promoting early events in angiogenesis, as well as endothelial cell function. Maximal activity occurs during a “window” period approximately 3 to 7 d after injury. Once the wound is granulated, angiogenesis ceases and blood vessels decline as endothelial cells undergo apoptosis. The reduction in VEGF and the loss of apoptosis may contribute to this transition from hypercellular granulation tissue to a hypocellular scar. A theoretical but clinically relevant side effect of topical VEGF therapy may be the development of a hypertrophic scar, though this has not been reported.

**SURGICAL APPLICATIONS OF VEGF AND THERAPEUTIC ANGIOGENESIS**

**Clinical Use of VEGF in Humans**

Phase I clinical trials have been initiated for patients with nonspecific limb ischemia [118, 119], Buerger’s disease [120], and myocardial ischemia [121]. As early as 1996, balloon transfer of plasmid DNA expressing VEGF was attempted on a nondiabetic patient with arterial occlusive disease in the lower extremity [118]. Following gene transfer to the distal popliteal artery, collateral vessels and flow to the leg were increased, and the site of transfer did not show intimal thickening. Although limb gangrene could not be reversed and the limb was eventually amputated, the experiment confirmed the feasibility of therapeutic angiogenesis for humans. The only reported adverse events were 3 spider angiomas, which resolved, and periph-

**FIG. 2.** VEGF and cellular basis of healing. Note the multiple roles that endogenous cells play in producing VEGF in the local wound environment. Platelets arrive first on Day “0” of wounding, followed by a peak of macrophages at Day 2. Endothelial cells begin to migrate at Day 2 and new capillary endothelium can be seen between Days 3 and 4. By Day 5, new collagen is produced from fibroblasts. The initial cell that releases VEGF are platelets which enter the wound after debridement. In addition, macrophages release VEGF, which stimulates endothelial cells to proliferate and migrate. VEGF has been shown to stimulate keratinocyte migration and collagen production via fibroblasts. VEGF secretion also induces release of other growth factors, which further stimulate healing. (Color version of figure is available online.)
eral edema in the treated leg, which was successfully treated with diuretics. More recently, intramuscular gene transfer of VEGF<sub>165</sub> to 9 patients with ischemic ulcers and/or rest pain secondary to peripheral arterial disease resulted in limb salvage for 3 and significantly decreased rest pain for all patients [119]. The only complication observed was transient edema in the treated lower extremities. With a similar experimental protocol, positive results have also been demonstrated in patients with advanced Buerger’s disease [120]. VEGF can partially reverse the ischemia of coronary heart disease. Plasmid-encoded VEGF injected directly into the myocardium of patients for whom conventional therapy for angina had failed resulted in a reduction of symptoms with improved coronary vasculature [121].

VEGF has shown positive and safe results administered alone or as adjunctive therapy to angioplasty and surgery [122–124]. An additional benefit in angioplasty may be secondary to prevention of restenosis in manipulated vessels.

Other Conditions that May Benefit From VEGF Therapy

There exist several clinical situations in which paucity of cellular mediators impairs wound healing. For example, dermal wounds of peripheral vascular disease patients mature more slowly and display fewer neutrophils and macrophages [125]. Wounds with transcutaneous oxygen pressures (TcPO<sub>2</sub>) of less than 20 mm Hg are slower to mature and patients with such wounds are more likely to have ulcers, rest pain, and amputation [126]. Furthermore, wound hypoxia limits neutrophil bactericidal activity and predicts infection in surgical patients [127, 128]. Therefore, VEGF may enhance and activate mononuclear cells and accelerate closure of nonhealing skin ulcers.

Diabetic Foot Ulcers and VEGF

Diabetes is the prototypical model of impaired wound healing. Patients with diabetes have decreased rates of tissue repair associated with low periwound TcPO<sub>2</sub> and blood pressure [129]. Notably, capillary density is reduced in the muscles of patients with non-Insulin-dependent diabetes [130]. The predisposition to ulceration in persons with diabetes has multifactorial and interrelated causes, including endothelial dysfunction, atherosclerosis, and peripheral neuropathy.

Multiple metabolic disturbances may be responsible for endothelial dysfunction, including oxidative stress, hyperglycemic pseudohypoxia, nonenzymatic glycation, and activation of the coagulation cascade [131, 132].

If the diabetic milieu favors VEGF expression, how is VEGF involved in the pathophysiology of diabetic wound healing? In accordance with this model, VEGF mRNA is elevated in the nonwounded skin of genetically diabetic mice. However, upon full-thickness excisional wounding, VEGF levels initially increase but eventually decrease to undetectable levels by d 5. During this time period granulation tissue is accumulating and VEGF peaks in nondiabetic, normal tissue [93]. Additionally, wounds of streptozotocin-induced diabetic mice demonstrate diminished synthesis of several growth factors, including VEGF [109]. In an ischemic hindlimb model of nonobese diabetic mice, impaired neovascularization is accompanied by diminished levels of VEGF mRNA and protein [133]. Finally, an acute drop from an elevated glucose concentration, which is an expected occurrence with diabetes, does not induce VEGF [134]. A discussion of why VEGF is not elevated in chronic wounds is outside the scope of this review. However, 1 can state that a defect in growth factor regulation is observed in diabetic wounds despite systemic and local conditions that actually favor their expression.

Healing of full-thickness wounds is intrinsically different in diabetic animals. Diabetic wounds tend to heal by cellular infiltration, deposition of granulation tissue, and reepithelialization, not by contraction, as occurs in wounds of normal animals. This pattern of wound closure is common to the tissue of chronic ulcers in patients with diabetes decubitus ulcers, and venous stasis [135]. Application of VEGF to a diabetic wound may enhance healing by promoting chemotaxis and angiogenesis. In addition, 1 of the mediators of VEGF activity, NO, enhances collagen deposition in diabetic wounds and may restore endothelial function to improve both nerve conduction and tissue oxygenation. In addition, new experimental data suggest that VEGF stimulates epithelialization and collagen production [27, 136].

Consistent with its mechanisms, VEGF may promote healing on multiple levels. Although PDGF is efficacious in diabetic ulcers [137], VEGF may stimulate additional components of wound healing independently of PDGF. VEGF alone or in combination with other treatment modalities may prove to be an effective treatment for diabetic vascular disease and ulcers. This possibility has recently been confirmed by the demonstration that gene therapy with VEGF restores the impaired angiogenesis found in ischemic limbs of diabetic mice [133]. Further rigorous study is needed to test the hypothesis that VEGF may be useful for treatment of pressure ulcers and diabetic foot ulcers.

Venous Stasis

The role of VEGF in chronic wounds secondary to venous insufficiency is also complex. Ulceration is thought to result from the accumulation and inappropriate activity of leukocytes [138, 139]. The release of cytokines, including TNF-α, promotes excess deposition of a fibrin cuff around capillaries, which causes a barrier to oxygen diffusion and possibly cell migration. Long-term consequences of leukocyte activity include en-
dothelial dysfunction, interstitial edema, microthrombi, and decreased capillary density. Hence, some degree of tissue hypoxia may be expected to impair wound healing. There is also an imbalance in the proteolytic environment of such wounds, with an overall elevation in matrix metalloproteinases and deficiency in their inhibitors [140–142].

Given the hypoxic pathologic environment of venous ulcers, plasma and tissue levels of VEGF are increased in patients with venous insufficiency, particularly those with ulcers [143, 144]. However, the functional level or presence of VEGF and its receptors at the wound site is unknown, and it is uncertain whether chronic venous wounds display a defect in angiogenesis. It might be expected that exogenously administered VEGF would improve perfusion and, hence, oxygenation, via angiogenesis. Moreover, VEGF may play a further role in epithelialization and collagen deposition if the presumed hypothesis regarding multiple nonangiogenic mechanisms is correct.

Pressure Ulcers

Decreased blood flow to the sacral areas is thought to contribute to the formation of pressure ulcers. Both low resting systolic pressure [145] and immobility leading to sustained external pressure [146] produce local skin ischemia in patients at risk for pressure ulcers (i.e., the elderly and persons recovering from spinal cord injury [147]). Loss of vasomotor control also contributes to poor perfusion [148]. Pressure ulcers have been treated successfully in randomized trials with the use of topically applied bFGF [149, 150]. Thus, angiogenic therapy may be a useful adjunct to pressure relief and skin care, once a wound has developed. Currently, no data exist for the efficacy of VEGF in pressure ulcer healing.

CONCLUSIONS

VEGF stimulates wound healing via multiple mechanisms including collagen deposition, angiogenesis, and epithelialization. In the clinical setting, the mitogenic, chemotactic, and permeability effects of VEGF may potentially aid in promoting repair in nonhealing wounds in arterial occlusive disease and diabetes. It may also alleviate the “wound” of ischemic heart disease. By promoting angiogenesis, VEGF improves tissue perfusion. Sustained release of VEGF (through adenovirus gene, biodegradable polymer, fibrin mesh, etc.) should be tested as rapidly as possible in patients with diabetic foot ulcers and pressure ulcers.

An important theme throughout this discussion has been the necessity of understanding the pathophysiology of chronic wounds. The distinct physiological impairments explain why a wound is slow to heal. The meaningful questions to ask when considering VEGF therapy are as follows: (1) is there a deficiency in angiogenesis or improper vascular function? (2) is there a deficiency or dysregulation of VEGF, its receptors, or VEGF signal transduction? (3) can VEGF therapy provide a positive effect? (4) to what extent is VEGF involved in epithelialization and collagen deposition? And (5) ultimately, can VEGF reverse any of these physiological impairments?

Complete understanding of wound pathophysiology and endogenous VEGF expression may help promote exogenous VEGF therapy for the closure of nonhealing wounds. Gene transfer studies have demonstrated the clinical efficacy of VEGF and the development of a human-grade protein will further clarify its role. PDGF is the only growth factor currently approved to treat wounds. The addition of VEGF, alone or in combination with other growth factors, may represent a significant step in the medical treatment of nonhealing wounds and other ischemic processes. VEGF may also have a future role as adjunctive therapy to accelerate healing and prevent complications in surgical revascularization, anastomoses, and plastic surgery.

ACKNOWLEDGMENT

This work received financial support through National Institutes of Health Grant 5K08DK059424.

REFERENCES

12. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel...


